About

Director since December 2015. Chief Medical Officer at Halozyme since October 2024; former President and CEO of Tracon Pharmaceuticals (2006-2024).

Roles

4D Molecular Therapeutics, Inc.
Director · Current role
2015–present

Director Compensation

FY 2025
Fees earned or paid in cash
$65,000
Option awards
$70,000
Total
$135,000

Also at 4D Molecular Therapeutics, Inc.

Colleague
David Kirn, M.D.
Co-Founder, President, Chief Executive Officer and Director
Colleague
John F. Milligan, Ph.D.
Director and Executive Chairman
Colleague
Jacob Chacko, M.D., MBA
Director

Related

Company
4D Molecular Therapeutics, Inc.
Company hub

See how VectorShift works for your firm

Request Demo